Saniona AB (publ) (SANION.ST)
Saniona AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Glostrup, CD, DK. The stock last traded at $9.71, down 1.12% on the session, giving a market capitalisation of $1.34B. Its beta of 1.20 implies it has historically moved more than the broad market.
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disorders. The company's pipeline features Tesofensine, a monoamine reuptake inhibitor, and Tesomet, a fixed-dose combination of tesofensine and metoprolol, which has advanced through Phase 2 clinical trials for Prader-Willi Syndrome and hypothalamic obesity. Additionally, Saniona is progressing SAN711, currently in Phase 1 for rare neuropathic conditions, and SAN903, an early-stage candidate in preclinical development for rare inflammatory, fibrotic, and hematological ailments. Saniona also engages in various strategic collaborations, including research and partnership agreements with Boehringer Ingelheim International GmbH, a licensing deal with Productos Medix, S.A. de C.V., and both research services and collaboration agreements with Cephagenix ApS.
Saniona AB (publ) is most often compared with the following Healthcare names: